SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending amid its Robinhood listing and strategic moves to integrate Real World Assets with NestCredit and implement PYTH Reserve token purchases. The community is actively debating its potential as a leading oracle solution, often comparing it to Chainlink, while also discussing concerns about token distribution and upcoming unlocks.

Nova Minerals Ltd. engages in the exploration and development of mineral properties. Its projects include Estelle Gold, RPM, Korbel, Train, Stoney and Studies projects. The company was founded in January 1987 and is headquartered in Melbourne, Australia.

Nova Minerals Limited - ADR

Nova Minerals is trending as it moves to redomicile in the United States, a strategic shift anticipated to attract institutional investors and US ETFs to its Estelle Gold and Critical Minerals Project. Community enthusiasm is also driven by its key antimony resources, backed by a significant government grant for US defense needs, and an upcoming forward stock split, all fueling discussions of its long-term potential.

Royal Gold, Inc. engages in the business of acquiring and managing precious metal streams, royalties, and similar interests. It operates under the Acquisition and Management of Stream Interests, and Acquisition and Management of Royalty Interests segments. The Acquisition and Management of Stream Interests segment focuses on metal streams, which are purchase agreements that provide, in exchange for an upfront deposit payment, the right to purchase all or a portion of one or more metals produced, at a price determined for the life of the transaction. The Acquisition and Management of Royalty Interests segment is involved in non-operating interests in mining projects that provide the right to revenue or metals produced from the project. The company was founded by Stanley Dempsey in 1981 and is headquartered in Denver, CO.

Royal Gold, Inc.

Royal Gold is trending as gold and silver prices reach new highs, with the community calling it a "money printer" due to its robust streaming model. The recent strategic acquisition of Sandstorm Gold, set to significantly boost GEO production and diversify its portfolio, fuels bullish sentiment despite varied analyst price target adjustments.

Tidal Trust II - YieldMax COIN Option Income Strategy ETF

YieldMax COIN Option Income Strategy ETF

YieldMax COIN Option Income Strategy ETF (CONY) is trending as it transitions to weekly dividend distributions, a move that is intensifying community debate around persistent NAV erosion and recent reverse splits, even as some investors advocate for disciplined, long-term income compounding strategies amidst underlying Coinbase volatility.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending amidst strong community conviction that a market bottom has been established and a Solana meme season is imminent, with many anticipating significant growth. Supporters are actively discussing its 'pure meme culture' and robust community, believing it's positioned for a major breakout.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as community discussion amplifies around its strategic pivot and hiring for robotics AI, underscoring its pivotal role in training artificial intelligence for the burgeoning humanoid and physical AI sectors, further bolstered by its significant partnership with Palantir and strong anticipation for its upcoming earnings.

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical, Risk, Legal Exhibitions and Print & print-related. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity. The Risk segment provides customers with solutions and decision tools that combine public and industry specific content with advanced technology and analytics to assist them in evaluating and predicting risk and enhancing operational efficiency. The Legal segment is a global provider of legal, regulatory and business information and analytics that helps customers increase productivity, improve decision-making and outcomes and advance the rule of law around the world. The Exhibitions segment is an event business, enhancing the effect of face-to-face through data and digital tools. The Print & print-related segment consistent with financial information provided to the board. The company was founded by Albert Edward Reed in 1903 and is headquartered in London, the United Kingdom.

RELX Plc - ADR

RELX is trending following positive earnings and strong cash conversion, but the market is sharply divided as fears of AI disruption, particularly from new legal tools like Anthropics Claude, clash with the company's "content is king" moat and accelerating AI-driven growth. Many in the community believe the stock is deeply undervalued, presenting a "generational buying opportunity" for its high-quality data and content assets.

Tidal Trust II - YieldMax Ultra Short Option Income Strategy ETF

SLTY is drawing attention from high-yield investors as a component of mechanical, 'inverted pair' strategies within the YieldMax ETF suite, valued for its consistent weekly dividends generated from option premiums. The community is actively discussing its utility as a potential bear market hedge and its performance in disciplined, rules-based systems focused on compounding and reinvestment.

Tidal Trust II - YieldMax Short NVDA Option Income Strategy ETF

YieldMax Short NVDA Option Income Strategy ETF

YieldMax Short NVDA Option Income Strategy ETF (DIPS) is trending as investors evaluate its recent dividend payouts and performance in response to NVIDIA's price action and market volatility. The community is actively discussing DIPS for its role in 'inverted pair' hedging strategies and as a high-yield option to gain exposure to potential NVDA downturns or balance existing bullish positions, amidst ongoing conversations about managing its inherent NAV decay.

Tidal Trust II - YieldMax Short COIN Option Income Strategy ETF

YieldMax Short COIN Option Income Strategy ETF

FIAT is trending as investors keenly observe its performance as a YieldMax ETF designed to short Coinbase, often utilized in inverted pair strategies for income generation. The community is actively discussing its latest dividend payouts and debating its effectiveness as a hedge against crypto market volatility, with some anticipating buying opportunities on price dips.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TG Therapeutics, Inc. $TGTX Shares Bought by Public Sector Pension Investment Board

Public Sector Pension Investment Board lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 14.5% during the 3rd quarter, according to its most recent 13F filing with the...

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat reports...

TG Therapeutics (NASDAQ:TGTX) Downgraded by Wall Street Zen to "Hold"

Wall Street Zen cut TG Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday...

<ul class="summary-bullets"><li>TG Therapeutics launched the NextInMS platform to support people living with multiple sclerosis.</li><li>Briumvi remains the key growth driver, with the company guiding to $825 million to $850 million in global revenue from the drug in 2026.</li><li>Wall Street sees upside, with JPMorgan and Goldman Sachs pointing to roughly 59% and 35% upside, respectively, from the stock’s last close.</li></ul>TG Therapeutics, Inc. sparked heightened retail chatter on Monday after unveiling a new multiple sclerosis (MS) awareness collaboration with Christina Applegate, which debuted during Super Bowl LX.<h2 class="st-heading-2">TG Launches NextInMS Platform</h2>The company launched NextInMS.com, a new platform designed to encourage open and informed conversations among people living with MS, caregivers, and healthcare professionals.Applegate, who has been living with MS for five years, is leading the campaign and will share personal perspectives on navigating the disease and making long-term decisions. TG Therapeutics said the platform will also feature educational content from MS experts.<h2 class="st-heading-2">Briumvi Fuels 2026 Growth Outlook</h2>The campaign comes as TG Therapeutics continues to build momentum around Briumvi, its approved treatment for relapsing forms of multiple sclerosis. The company reported preliminary full-year 2025 global revenue of about $616 million, driven largely by Briumvi, which generated $594 million in U.S. net product revenue. Fourth-quarter U.S. net product revenue was estimated at roughly $182 million.The company also guided to a full-year 2026 total global revenue of $875 million to $900 million, including $825 million to $850 million in U.S. net product revenue from Briumvi. The company said it expects growth to be supported by ongoing commercial execution and efforts to further improve treatment convenience.Last year, TG Therapeutics completed enrollment in the Phase 3 Enhance trial evaluating a simplified intravenous dosing schedule for Briumvi, with topline data expected in mid-2026. The company also plans to announce pivotal topline data for a self-administered subcutaneous formulation around year-end 2026 or early 2027, alongside additional exploratory studies that could expand Briumvi’s use beyond multiple sclerosis.TG Therapeutics' six-year results showed that nearly 90% of patients on continuous Briumvi treatment remained free from disability progression, with a low annualized relapse rate and no new safety signals reported over extended follow-up.<h2 class="st-heading-2">Wall Street Sees Upside In TGTX Stock</h2>Earlier this month, JPMorgan lowered its price target on TG Therapeutics to $46 from $49, implying a 59% upside from the stock’s last close, while maintaining an ‘Overweight’ rating.&nbsp;On the other hand, Goldman Sachs raised its price target to $39 from $37, implying a 35% upside from current levels, and reiterated a ‘Neutral’ rating. The brokerage pointed to the company’s 2026 revenue guidance and progress in the Briumvi program.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TGTX was ‘bullish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/tgtx_ss_png_fa811bf158.webp" alt="tgtx ss.png" width="972" height="139"><figcaption>TGTX sentiment and message volume as of February 9 | Source: Stocktwits</figcaption></figure>One user said, “TG actually partnered with Christina Applegate. She brings her authentic lived experience, it will expand brand visibility more than ever, build MORE trust with patients and providers, and will support B organically. Huge win for TG. If MW wanted to, its an easy sale from here..”<stembedurl>https://stocktwits.com/Insidersknow/message/644419693</stembedurl>Another user speculated that greater visibility around Christina Applegate’s treatment experience with TG Therapeutics could further boost the stock, saying, “TG rockets with even more impressive sales.”<stembedurl>https://stocktwits.com/PotionX1900/message/644429350</stembedurl><a href="https://stocktwits.com/symbol/TGTX">TGTX stock</a> has declined 14% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Christina Applegate (L) speaks onstage during the Light Up The Blues 7 Concert celebrating Autism Speaks' 20th Anniversary at the Greek Theatre on April 26, 2025 in Los Angeles, California. (Photo by Kevin Winter/Getty Images)

TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win'

TG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression.

Equity

Universal Beteiligungs und Servicegesellschaft mbH Has $2.29 Million Stake in TG Therapeutics, Inc. $TGTX

Universal Beteiligungs und Servicegesellschaft mbH lessened its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 67.1% during the third quarter, according to the company in...

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat reports...

Q4 EPS Estimates for TG Therapeutics Raised by HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at HC Wainwright raised their Q4 2025 earnings per share estimates for TG Therapeutics in a research report issued to clients and...

TG Therapeutics (NASDAQ:TGTX) Trading 7.5% Higher - Here's Why

TG Therapeutics (NASDAQ:TGTX) Stock Price Up 7.5% - Here's What Happened...

HC Wainwright Forecasts TG Therapeutics FY2025 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at HC Wainwright raised their FY2025 EPS estimates for TG Therapeutics in a research report issued to clients and investors on...

Currency and Exchange Stock Chart for Finance and Economy Display. (Image Courtesy: Getty Images)

TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally

Strong 2026 guidance and accelerating uptake of its MS drug send TGTX to its best session in months, with Wall Street and retail piling in.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$28.50
Prev Close	$28.42
Open	$28.65
Dividend Yield	0.00%
50-Day Moving Average	$30.14
Beta	1.06
Avg. Volume	2.5M
PE Ratio	10.26

52-Week High	$46.48
52-Week Low	$25.28
Market Capitalization	$4.53B
EPS (Annual)	$0.1458
Price to Book	7.28
Revenue Per Employee	$973,384.61

TGTX
TG Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TGTX News

TGTXTG Therapeutics Inc